{"disease":{"id":"her2-positive-locally-advanced-or-metastatic-breast-cancer","name":"her2 positive locally advanced or metastatic breast cancer"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT02514681","title":"A Phase III Trial of Pertuzumab Retreatment in Previously Pertuzumab Treated Her2-Positive Advanced Breast Cancer","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":226,"lead_sponsor_name":"Japan Breast Cancer Research Group","has_results":false},{"nct_id":"NCT07182721","title":"SKB264 Plus Inetetamab in HER2-Positive Metastatic Breast Cancer Patients Progressing After T-DXd Treatment","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":48,"lead_sponsor_name":"Fudan University","has_results":false}],"total":2},"guidelines":[],"source":"Drug Landscape verified database"}